Spinocerebellar Degenerations
A heterogenous group of degenerative syndromes marked by progressive cerebellar dysfunction either in isolation or combined with other neurologic manifestations. Sporadic and inherited subtypes occur. Inheritance patterns include autosomal dominant, autosomal recessive, and X-linked.
Subtype terms (4)
More specific conditions that are subtypes of Spinocerebellar Degenerations in the MeSH hierarchy.
- Friedreich Ataxia
37 drugs (20 approved, 17 experimental)
- Myoclonic Cerebellar Dyssynergia
- Olivopontocerebellar Atrophies
- Spinocerebellar Ataxias
14 drugs (6 approved, 8 experimental)
Drugs by status
Phase 4 trials (1)
Phase 3 trials (1)
Phase 2 trials (3)
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (8)
Organization Involved with Phase 2 Indications (16)
- Pfizer
- Baxalta
- Bioblast Pharma Ltd.
- Sclnow Biotechnology Co., Ltd.
- Steminent Biotherapeutics Inc.
- National Institute of Neurological Disorders and Stroke (NINDS)
- Central South University
- Nanjing Medical University
- Nanjing University
- University of South Florida
- Xuzhou Medical University
- Tel Aviv University
- University of Naples Frederico II
- Beike Biotech
- Bob Allison Ataxia Research Center
- Cadent Therapeutics
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (5)